Trial Profile
A Randomised, Single-dose, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0142-0002 in Subjects With Active Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Tesnatilimab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 24 Apr 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov.
- 24 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Apr 2012 European Clinical Trials Database record reports trial status completed.